CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Angel Biotechnology Holdings Plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Angel Biotechnology Holdings Plc
The Doherty Building, Bush Loan
Pentlands Science Park Penicuik
Phone: +44 1314456077p:+44 1314456077 EDINBURGH, ENG  EH26 0PZ  United Kingdom Ticker: ABHABH
Filed for Bankruptcy on 2/11/2013
On 1/28/13, the Company announced that it needed to enter into a strategic relationship with another party to develop more effectively its contract manufacturing business and that it had for some time been in discussions with a consortium of overseas organisations in this connection. The Company also stated that in the opinion of the Board, this arrangement was essential to the ongoing viability of the Company. Discussions with that consortium were terminated, and as a result the Company requested immediate suspension of trading in its Ordinary Shares on AIM. On 2/8/2013, the Company's stock was suspended. On 2/11/2013, the Company appointed administrators.
This company is no longer actively traded on any major stock exchange.
Business Summary
Angel Biotechnology Holdings Plc is a specialist biopharmaceutical manufacturing company. The Company is engaged in the manufacture and supply of biologics, biological products whose active ingredients cannot be chemically synthesized. The Company supplies the biopharmaceuticals contract manufacturing sector of the biologics market and within that sector focuses on the early-stage drug development work, such as chemistry, manufacturing and controls, and pre-clinical studies, along with drug products for Phases I, II and III of clinical trials. The Company specializes in the manufacture and development of recombinant proteins, cellular therapies and stem cells, antibodies and viruses. The Company operates out of two sites: Pentlands Science Park near Edinburgh and Cramlington near Newcastle upon Tyne. On May 9, 2012, the Company acquired assets of an biomaterial and collagen manufacturing business, through its newly formed and wholly owned subsidiary, Angel Biomedical Ltd (ABL).
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20123/31/2012Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Nicholas J.Smith 10/12/2012 9/17/2008
Acting Chief Executive Officer, Commercial Director, Executive Director StewartWhite 3/5/2012 12/5/2011
Group Finance Director, Company Secretary, Executive Director Lorna A.Peers 3/16/2011 6/7/2010
Senior Independent Non-Executive Director Gavin D.Clark 1/1/2008 12/4/2007

Business Names
Business Name
ABH
Angel Biomedical Ltd.
Angel Biotechnology Holdings Plc

General Information
Number of Employees: 37 (As of 3/31/2012)
Outstanding Shares: 3,773,616,615 (As of 9/30/2012)
Stock Exchange: SEA
Fax Number: +44 1314456071


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023